Ann: Skin scarring webinar featuring Professor Fiona Wood, page-27

Once the SNT 5505 Trial is completed IMHO SNT will be in the sweet spot as an acquisition target ,,, Big Pharma just don't require SNT for the Phase III

Fiona has all the necessary market and industry allies to commercialise SNT 9465...

My personal view is the Company PR and Marketing is a little weak but even that seems to be improving presently ... the reason the SP hasn't gained any real traction lately is the endless selling down to Buyers... SNT should have cleared 10c on the current offerings at the stage they are at now..

Thank heavens it's Friday ,,,, busiest day of the week ,, Tight hands required ,,, Best of Luck to all invested NZT